U.S. Markets close in 3 hrs 30 mins

Neptune Technologies & Bioressources Inc. (NEPT)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
0.8474-0.02 (-1.81%)
As of 12:25PM EDT. Market open.
People also watch
  • TEST
  • only one person posting here??? not much interest in this stock... tumbling!
  • what is the value of the license to commercialize?
  • how about someone other than one pumping guy..put a meaningful post on here!!!
  • Did anyone else see $NEPT report from http://jcharlesassets.com/clients-2/?s=NEPT ? It had some interesting information. Making money day trading. "rht"

  • need to BRAND there OIL and sell it on line and into retail as well of course but the best margins will be on line direct sales of course u do all of it and intl as well. Takes a lot of flower to produce the high quality oil = land = green houses and storage
  • MEXICO [ the cartel country ] = Medical Pot = LEGAL 2 ish days ago [ the RACE is on in North America thats for sure ]
  • (AXSM) Mcap $90 M /Cash $55 M / 5x Phase 3 programs in various indications targeting huge Markets with first results in Q3 2017 =10+ BAGGER ....GLTA !

    Undiscovered and massive undervalued Biotech Stock with lots of Big News on the way.This Stock is brutally undervalued with a Market cap of just $90 million and $55 million in cash .Founder and Ceo is the larget shareholder holding over 7 million shares (30%) more than 50% of O/S is owned by Insider and Institutions which is a great sign .

    This undiscovered stock could be the next 10 bagger gem if just one of their 5 ongoing Phase 3 programs is successful .GL

    Axsome (AXSM)

    Market-Cap: $90 Million
    Cash: $55 Million(cash runway into the first quarter of 2019.)

    Shares Out: 23.5 Million

    Aegis Capital has reiterated a ‘Buy’ rating and price target of $20 on Axsome Therapeutics (NASDAQ: AXSM) after the company reported financial results for the quarter ended March 31, 2017. The analyst noted that although Axsome reported revenue in-line with consensus estimates, the focus remains on upcoming catalysts such as the company’s ongoing clinical trials. Since February 2017, the company’s AXS-05 has received fast track designation from the FDA for the treatment of Alzheimer’s disease (AD) agitation and treatment resistant depression (TRD). Topline data from the TRD treatment study is expected in the first quarter of 2018. Additionally, Axsome is developing AXS-02 in three separate phase 3 clinical programs, including chronic low back pain associated with modic changes and complex regional pain syndrome, with interim data expected in the fourth quarter of 2017, as well as knee osteoarthritis associated with bone marrow lesions, with interim data expected in the third quarter of 2017.
  • 1 Gram of high quality of THC / CBD OIL = about $ 90.00 us dllrs retail / it is my hope with this plant they will have other growers as customers in addtion to there own crop...and re ACST and there care pre the sooner the better
  • News CRME and see BUDZ News today re MYMMF traded over 11 mill shares on the CSE Yesterday
  • i dont see any valuation problem and i do see growth and a better bal sheet so i will take more
  • OMEGA 3 MKT 26 ODD BILL IN 2016 57 BILLIN 2025 as per report buyer = NEPT / CARE PRE = ASCT = LAUNCH
  • LONG CRME NEPT CDNA pure on a pull back and MYMMF .......previous post symbol is MYMMF sorry about that. Wow 6 posters here and climbing up from 1 i like the trend. MYMMF about 20 25 times avg vol no time to check
  • MWMMF Closed up 40 % was in the 50 odd % intraday ......news out today / now tomm will be intresting re a pull back or HIGHER no one knows / bought that right on the open. NEPT come ing back up from way over sold T / A WISE
  • See THCX.V NEWS today looks quite intresting re news and bal sheet [ need to more FUNDI ] first
  • check out this article! See the potential?

    Chart: U.S. marijuana industry’s economic impact to approach $70B by 2021 - Marijuana Business Daily

    Marijuana Business Daily
    About Marijuana Business Daily | Advertise
    News by Topic Data ChartsIndustry DirectoryBusiness Books Fall ConferenceMagazine
    Home > Featured > Chart: U.S. marijuan...
    June 12, 2017 Chart: U.S. marijuana industry’s economic impact to approach $70B by 2021

    By Eli McVey

    The U.S. cannabis industry is poised to inject nearly $70 billion on an annual basis into the American economy by 2021, an eye-popping figure that underscores the broader economic impact for towns and municipalities that accept legal marijuana businesses into their communities.

    Estimates published in the newly released Marijuana Business Factbook 2017 show the total economic impact of legal marijuana sales rising from $16 billion-$18 billion in 2016 to $48 billion-$68 billion by 2021 – a 241% increase.

    By comparison, the $68 billion figure is similar to the 2016 gross domestic products of the Dominican Republic ($72 billion) and Kenya ($67 billion), according to International Monetary Fund data.

    The projections are another example of marijuana’s rapid transformation from an industry dominated by black-market players into a legitimate and considerable economic force, quickly becoming a major job generator and bringing new business opportunities that produce significant ripple effects across the country.

    Based on sales of medical and recreational marijuana at the retail level – including flower, infused products and concentrates – the estimates use an economic multiplier of four to quantify the industry’s overall contribution to the economy, showing how revenue generated by cannabis businesses percolates through communities, cities, states and the nation.

    In other words, for each dollar spent by marijuana patients/customers at the retail level, an additional $3 in economic benefit is realized – much of it at the local level.

    Following are examples of how marijuana businesses affect the economy:

    Wages paid to employees of cannabis companies benefit many other local businesses, given that workers spend a portion of their earnings to buy food from a grocery store or dine at a restaurant.
    Marijuana businesses collectively pay hundreds of millions of dollars in state and local taxes, which fund projects including roads and rural hospitals as well as government programs such as education.
    The launch of a new cannabis business – cultivation facilities, in particular – generate real estate and construction activity, often in economically disadvantaged areas of a town or municipality.
    With recreational or medical legalization measures passed in 11 markets last year and several more states that have previously legalized marijuana – including Hawaii and Maryland – set to launch in the coming months, the cannabis industry is poised for strong, continual growth well into the future.

    Furthermore, sales in existing medical and recreational markets have shown no signs of slowing. In Washington state and Colorado, for example, adult-use sales in the first two months of 2017 broke records.

    Consequently, the cannabis industry’s impact on the broader economy will be even greater as time goes on. That may spur public officials to revisit their stance toward marijuana legalization, given the economic upsides that cannabis businesses can bring to the table.

    Eli McVey can be reached at elim@mjbizdaily.com

    Daily News | Featured | Marijuana Industry Data and Charts | Sales, Funding & Banking News